{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Section', 'Change', 'Rationale', '8.4.3. Tertiairy Endpoint', '-', '\"Ctrough: plasma concentration observed', 'Analyses', 'pre-dose at Visits 2, 3 and 4\"', 'changed to', '\"Ctrough: serum concentration observed', 'pre-dose at Visits 2, 3 and 4\"', '11.1 Data Handling and Record', '-', 'First sentence:', 'Updated to avoid duplication', 'Keeping', '\"It is the Investigator\\'s responsibility to', 'of information.', 'maintain essential trial documents', '(including regulatory documents,', 'eCRFs, signed patient ICFs, source', 'documents, \"', 'changed to', '\"It is the Investigator\\'s responsibility to', 'maintain essential trial documents', '(records and documents pertaining to', 'the conduct of this trial and the', 'distribution of IMP, including', 'regulatory documents, eCRFs, signed', 'patient ICFs, laboratory test results,', 'IMP inventory records, source', 'documents, \"', '-', 'Third paragraph (\"The United States', '(US) Food and Drug Administration', '(FDA) regulations the Principal', 'Investigator of these events.\") deleted.', '-', 'The following sentence was added to', 'the end of the first paragraph:', '\"The Sponsor will notify the Principal', 'Investigator of these events.\"', 'Appendix 6', 'Laboratory', '\"**\" changed to \"1\"', 'Updated for extra', 'Evaluations', 'clarification.', 'Clinical Chemistry', 'AChR-/MuSK-antibody', '-', 'was added to the end of the', 'serotype', 'description.', 'Footer', '-', '\"**\" changed to \"1\"', '-', '\" In case the AChR-Ab result is not', 'available in time (within the 2 weeks', 'screening window), the value found in', 'the Medical History of the patient will', 'be used for randomization.\" was added.', 'CCI', 'argenx BVBA', 'Confidential', 'Page 16 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Section', 'Change', 'Rationale', 'Appendix 8 Decision Tree for', 'Figure and footnote added.', 'Added for completeness', 'Re-treatment - Part A', 'Appendix 9 Decision Tree for Figure and footnote added.', 'Added for completeness', 'Re-treatment - Part B', 'argenx BVBA', 'Confidential', 'Page 17 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'SYNOPSIS', 'Name of Sponsor:', 'argenx BVBA', 'Name of Investigational', 'ARGX-113 (efgartigimod)', 'Medicinal Product (IMP):', 'Name of Active Ingredient:', 'A human anti-neonatal Fc- receptor (FcRn) immunoglobulin G1 (IgG1)', 'Fc fragment', 'Indication:', 'Treatment of patients with generalized myasthenia gravis (gMG)', 'Title of Trial:', 'A randomized, double-blind, placebo-controlled, multicenter Phase 3 trial to evaluate', 'the efficacy, safety and tolerability of ARGX-113 in patients with myasthenia gravis', 'having generalized muscle weakness', 'Protocol No:', 'ARGX-113-1704 (ADAPT)', 'Trial Sites:', 'This trial is a global, multicenter trial', 'Trial Duration: The trial duration is 26 weeks preceded by a Screening', 'Phase: 3', 'period of maximum approximately 2 weeks.', 'Objectives:', 'Primary Objective:', 'To evaluate the efficacy of ARGX-113 as assessed by the percentage of \"Myasthenia Gravis Activities of', 'Daily Living (MG-ADL) responders\" after the first Treatment Cycle in the acetylcholine receptor', '(AChR)-antibody (Ab) seropositive population.', 'Secondary Objectives:', 'To evaluate the efficacy of ARGX-113 as assessed by the percentage of \"Quantitative Myasthenia Gravis', '(QMG) responders\" after the first Treatment Cycle in the AChR-Ab seropositive population.', 'To evaluate the efficacy of ARGX-113 as assessed by the percentage of \"MG-ADL responders\" after the', 'first Treatment Cycle in the overall population (AChR-Ab seropositive and AChR-Ab seronegative', 'patients).', 'To evaluate the efficacy of ARGX-113 as assessed by the percentage of time that patients show a', '\"clinically meaningful improvement\" in total MG-ADL score during the trial (up to and including Day', '126) in the AChR-Ab seropositive population.', 'To evaluate the efficacy of ARGX-113 as assessed by the time to qualification for first re-treatment in the', 'AChR-Ab seropositive population.', 'To evaluate the onset of efficacy of ARGX-113 as assessed by the percentage of \"early MG-ADL', 'responders\" after the first Treatment Cycle in the AChR-Ab seropositive population.', 'To evaluate the safety and tolerability of ARGX-113 in the overall population and in subgroups.', 'Tertiary Objective:', 'To assess additional efficacy and safety parameters, pharmacodynamics (PD) and immunogenicity.', 'Definitions', 'An \"MG-ADL responder\" is defined as a patient who shows a decrease of at least 2 points on the total', 'MG-ADL score (compared to the corresponding Treatment Cycle Baseline [TCB]) for at least 4 consecutive', 'weeks with the first of these decreases occurring at the latest 1 week after last infusion of IMP of the', 'corresponding cycle. The scoring of MG-ADL should be performed by a trained and certified evaluator.', 'argenx BVBA', 'Confidential', 'Page 18 of 110']\n\n###\n\n", "completion": "END"}